浏览全部资源
扫码关注微信
1.河南中医药大学医学院,郑州 450046
2.河南中医药大学中医药科学院,郑州 450046
3.河南中医药大学药学院,郑州 450046
Published:15 July 2023,
Received:09 December 2022,
Revised:14 May 2023,
扫 描 看 全 文
石文博,李嫚,曾华辉等.黄体酮共晶制备及其体内安全性研究 Δ[J].中国药房,2023,34(13):1567-1572.
SHI Wenbo,LI Man,ZENG Huahui,et al.Study on preparation and in vivo safety of progesterone cocrystal[J].ZHONGGUO YAOFANG,2023,34(13):1567-1572.
石文博,李嫚,曾华辉等.黄体酮共晶制备及其体内安全性研究 Δ[J].中国药房,2023,34(13):1567-1572. DOI: 10.6039/j.issn.1001-0408.2023.13.05.
SHI Wenbo,LI Man,ZENG Huahui,et al.Study on preparation and in vivo safety of progesterone cocrystal[J].ZHONGGUO YAOFANG,2023,34(13):1567-1572. DOI: 10.6039/j.issn.1001-0408.2023.13.05.
目的
2
制备黄体酮-2-氯-4-硝基苯胺(CNA)共晶以提高黄体酮的水溶性,并初步评价其体内安全性。
方法
2
选用黄体酮为共晶主体,CNA为共晶配体,采用溶剂挥发法制备黄体酮-CNA共晶。通过单晶X射线衍射、粉末X射线衍射、差示扫描量热、红外光谱等技术对共晶进行表征,并对比共晶与黄体酮原料药、黄体酮与CNA物理混合物之间的溶出度差异。将48只雌性KM小鼠随机分为正常组(含0.1%二甲基亚砜的磷酸盐缓冲液)、黄体酮组(16 mg/kg)、CNA组(9 mg/kg)和黄体酮-CNA共晶低、中、高剂量组(6、12.5、25 mg/kg),每组8只;肌内注射相应药物/溶剂,每天给药1次,连续14 d。通过测定/观察小鼠体质量、脏器指数、组织形态、血常规及肝肾功能指标变化来初步评价共晶的安全性。
结果
2
单晶X射线衍射实验结果中新晶型结构的出现、粉末X射线衍射图谱里新特征峰的出现、差示扫描量热检测结果中熔点的改变以及红外光谱图中3 500 ~2 750、1 700~1 250 cm
-1
范围内特征峰位置的改变,均表明黄体酮-CNA共晶制备成功,且所制共晶的溶出速率比黄体酮原料药提高了1倍以上。体内安全性实验结果显示,各组小鼠死亡率均为零。与正常组比较,黄体酮组及黄体酮-CNA共晶各剂量组小鼠子宫指数均显著升高(
P
>0.05),子宫内膜也有所增厚;各组小鼠体质量、肝肾功能、肝脏指数、肾脏指数以及白细胞、淋巴细胞、中性粒细胞数量差异均无统计学意义(
P
>0.05),肝肾组织形态无差异;黄体酮组小鼠红细胞数量显著减少(
P
<0.05),但黄体酮-CNA共晶各剂量组小鼠红细胞数量差异均无统计学意义(
P
>0.05)。
结论
2
成功制备了黄体酮-CNA共晶,提高了黄体酮原料药的水溶性,且所制黄体酮-CNA共晶的体内安全性较好。
OBJECTIVE
2
To prepare progesterone-2-chloro-4-nitroaniline cocrystal (CNA) so as to improve the solubility of progesterone and primarily evaluate the safety of the progesterone cocrystal
in vivo
.
METHODS
2
Using progesterone as the main body and CNA as the ligand, progesterone-CNA cocrystal was prepared with solvent evaporation method. The cocrystal was characterized by X-ray single crystal diffraction, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (IR). The dissolution rate of cocrystal was compared with those of progesterone and physical mixture. Forty-eight female KM mice were randomly divided into normal group (phosphate buffer containing 0.1% dimethyl sulfoxide), progesterone group (16 mg/kg), CNA group (9 mg/kg), progesterone-CNA cocrystal low-dose, medium-dose and high-dose groups (6, 12.5, 25 mg/kg), with 8 mice in each group. They were given relevant medicine/solvent intramuscularly, once a day, for consecutive 14 d. The safety of cocrystal was evaluated primarily by determining/observing the changes in body weight, organ index, tissue morphology, blood routine indicators, and liver and kidney function indicators.
RESULTS
2
The new crystal structure in the X-ray single crystal diffraction results, the new characteristic peak in the XRPD pattern, the change of melting point in the DSC results, and the change of the characteristic peak position in the range of 3 500- 2 750 cm
-1
and 1 700-1 250 cm
-1
in the infrared spectrum all indicated that progesterone-CNA cocrystal was successfully prepared, and the dissolution rate of cocrystal was more than twice that of the progesterone raw material drug. The results of
in vivo
safety experiments showed that the mortality rate of all groups was zero. Compared with normal group, uterine indexes of mice in progesterone group and progesterone-CNA cocrystal groups were significantly increased (
P
>0.05), and endometrium was also thickened; there was no statistical difference in the changes of body mass, liver and kidney function, liver index, kidney index, the number of leukocyte, lymphocyte and neutrophil in routine blood test among those groups (
P
>0.05), and the morphology of liver and kidney tissue has also no significant difference. However, the number of plasma red blood cells in the progesterone group decreased significantly (
P
<0.05), and there was no statistical significance in the number difference of red blood cells among progesterone-CNA cocrystal groups (
P
>0.05).
CONCLUSIONS
2
The progesterone-CNA cocrystal is successfully prepared with good safety
in vivo
, which significantly improve the solubility of progesterone.
黄体酮共晶表征分析体内安全性
cocrystalcharacterization analysissafety in vivo
GUAN D,XUAN B F,WANG C G,et al. Improving the physicochemical and biopharmaceutical properties of active pharmaceutical ingredients derived from traditional Chinese medicine through cocrystal engineering[J]. Pharmaceutics,2021,13(12):2160.
WANG J E,DAI X L,LU T B,et al. Temozolomide-hesperetin drug-drug cocrystal with optimized performance in stability,dissolution,and tabletability[J]. Cryst Growth Des,2021,21(2):838-846.
刘立新,邹冬玉,张羽男,等. 木犀草素·4,4′-联吡啶药物共晶对小鼠巨噬细胞RAW264.7的抗炎作用研究[J]. 中国药房,2018,29(5):602-606.
ROSS S A,LAMPROU D A,DOUROUMIS D. Engi- neering and manufacturing of pharmaceutical co-crystals:a review of solvent-free manufacturing technologies[J]. Chem Commun,2016,52(57):8772-8786.
ZHOU W X,ZHAO H W,CHEN H H,et al. Characterization of drug-drug salt forms of metformin and aspirin with improved physicochemical properties[J]. Cryst Eng Comm,2019,21(25):3770-3773.
THAKURIA R,SARMA B. Drug‑drug and drug‑nutra- ceutical cocrystal/salt as alternative medicine for combination therapy:a crystal engineering approach[J]. Crystals,2018,8(2):101.
杨通飞,李庆琼,邱璐. 黄体酮临床应用现状及研究进展[J]. 中国现代医生,2022,60(18):220-224.
李学娥,张蜀,闵杰. 黄体酮的新剂型及其相关应用研究进展[J]. 广东药科大学学报,2019,35(5):697-701.
夏勇涛. 2-氯-4-硝基苯胺在UASB+A/O电化学耦合系统中降解特性研究[D]. 南昌:南昌大学,2022.
国家药典委员会.中华人民共和国药典:四部[M]. 2020年版.北京:中国医药科技出版社,2020:107.
王安妮,冯欣,赵志刚. 先兆流产药物治疗策略进展[J]. 临床药物治疗杂志,2019,17(2):32-35.
FRIŠČIĆ T,LANCASTER R W,FÁBIÁN L,et al. Tu- nable recognition of the steroid α-face by adjacent π-electron density[J]. Proc Natl Acad Sci U S A,2010,107(30):13216-13221.
严银银,闫敏,武香香,等. 藏红花素对雷公藤甲素致小鼠脏器损伤的保护作用研究[J]. 中国药房,2021,32(19):2320-2326.
WANG X,JIANG Z,XING M,et al. Interleukin-17 mediates triptolide-induced liver injury in mice[J]. Food Chem Toxicol,2014,71:33-41.
孙青苗,金彦,陈捷,等. 肌肉注射黄体酮致局部不良反应相关因素分析[J]. 中国药物应用与监测,2009,6(5):300-302.
BENCAIOVA G,BREYMANN C. Acquired sideroblastic anaemia following progesterone treatment in pregnancy[J]. Aust N Z J Obstet Gynaecol,2009,49(2):235-236.
陈英,孟茜,刘佳,等.黄芪酊涂擦对肌肉注射黄体酮所致局部皮肤不良反应的疗效观察[J].当代护士,2021,28(9):144-145.
0
Views
5
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution